From: RIMN@nnpi.com
Sent: Thursday, November 14, 2002 2:37 PM
To: FDADockets@oc.fda.gov
Cc: mkramer@oc.fda.gov; MAMC@nnpi.com; MHOD@nnpi.com
Subject: FW: Combination Products - Public Hearing /Nov 25, 2002

Dear Mark,
Just to let you know that Mary Ann McElligott and I have decided to
participate remotely in the public hearing on FDA Regulation of Combination
Products (scheduled for November 25) by audio conferencing.  Please e-mail
me at rimn@nnpi.com the additional instructions and the call-in telephone
number to access this hearing.

Sincerly,
Rima B. Nassar	

>  -----Original Message-----
> From: 	Nassar, Rima (RIMN)  
> Sent:	Friday, November 08, 2002 2:56 PM
> To:	'FDADockets@oc.fda.gov'
> Cc:	'mkramer@oc.fda.gov; McElligott, Mary Ann (MAMC); Hodiwala, Meher
> (MHOD)
> Subject:	Combination Products - Public Hearing /Nov 25, 2002
> 
> Dear Mark,
> This is to inform you that Novo Nordisk Pharmaceuticals, Inc., in
> Princeton, New Jersey plans to participate in the public hearing on FDA
> Regulation of Combination Products to be held on November 25, 2002 at
> DoubleTree Hotel in Rockville, Maryland.  The two participants are:
> 
> Mary Ann McElligott, Ph.D.
> Senior Director
> Regulatory Affairs, Diabetes and WHC
> and 
> 
> Rima B. Nassar, Ph.D.
> Assistant Director,
> Regulatory Affaris, Diabetes and WHC
> 
> Thank you very much for your assistance, and we look forward to a
> successful and productive outcome of the hearing.
> 
> Sincerely,
> Rima Nassar
>